Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb;59(1):e14152.
doi: 10.1111/1475-6773.14152. Epub 2023 Mar 29.

The effects of patient out-of-pocket costs on insulin use among people with type 1 and type 2 diabetes with Medicare Advantage insurance-2014-2018

Carrie McAdam-Marx  1 , Natalia Ruiz-Negron  2 , Jane M Sullivan  3 , Jamie M Tucker  3
Affiliations

The effects of patient out-of-pocket costs on insulin use among people with type 1 and type 2 diabetes with Medicare Advantage insurance-2014-2018

Carrie McAdam-Marx et al. Health Serv Res. 2024 Feb.

Abstract

Objective: To identify the association between insulin out-of-pocket costs (OOPC) and adherence to insulin in Medicare Advantage (MA) patients.

Data sources and study setting: The study is based on Optum Labs Data Warehouse, a longitudinal, real-world data asset with de-identified administrative claims and electronic health record data.

Study design: Using descriptive and multivariable logistic regression analyses, we identified the likelihood of patients with diabetes having ≥60 consecutive days between an expected insulin fill date and the actual fill date (refill lapse) by OOPC, categorized by $0, >$0-$20 (reference), >$20-$35, >$35-$50, and > $50 per 30-day supply.

Data collection/extraction methods: The study included MA enrollees with type 1 or type 2 diabetes and prescription claims for insulin between 2014 and 2018.

Principal findings: Those with average insulin OOPC per 30-day supply >$35 or $0 were more likely to have an insulin refill lapse versus OOPC of >$0 to $20, with odds ratios ranging 1.18 (95% CI 1.13-1.22) to 1.74 (95% CI 1.66-1.83) depending on OOPC group and diabetes type.

Conclusions: Capping average insulin OOPC at $35 per 30-day supply may help avoid cost-related insulin non-adherence in MA patients; efforts to address non-cost barriers to medication adherence remain important.

Keywords: Medicare Advantage; cost-share; diabetes; insulin; medication adherence.

PubMed Disclaimer

References

    1. American Diabetes Association . Support Affordable Insulin & Health Equity. American Diabetes Association; 2017. https://www.diabetes.org/get-involved/advocacy/platform/bill-support-wat.... Accessed February 17, 2022.
    1. Cefalu WT, Dawes DE, Gavlak G, et al. Insulin access and affordability working group: conclusions and recommendations. Diabetes Care. 2018;41(6):1299‐1311. - PubMed
    1. Relative to Copayments for Insulin, Establishing a Wholesale Prescription Drug Importation Program, Establishing a New Hampshire Prescription Drug Affordability Board, Establishing the Prescription Drug Competitive Marketplace, Relative to the Pricing of Generic Prescription Drugs, Relative to Prior Authorization for Prescription Drug Coverage, and Requiring Insurance Coverage for Epinephrine Auto‐Injectors. In. Muscatel L, Stevens, Grassie , Merchant, et al., trans. LegiScan; 2020. https://legiscan.com/NH/text/HB1280/2020. Accessed March 21, 2023.
    1. Ault A, More US. States Cap Insulin Costs, but Activists will ‘Fight Harder’. Medscape; 2020. https://www.medscape.com/viewarticle/936825. Accessed Feburary 17, 2021
    1. American Diabetes Association . Insulin and Drug Affordability. American DIabetes Association; 2022. https://diabetes.org/advocacy/insulin‐and‐drug‐affordability?utm_source=.... Accessed April 20, 2022.

Publication types